Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GLPG

Galapagos NV ADR

Apr 16 • 01:40PM ET

29.51

Dollar change -0.29
Percentage change -0.97	%

Healthcare • Biotechnology • Belgium • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.32	Insider Own	0.94%	Shs Outstand	65.90M	Perf Week	-6.76%
Market Cap	1.94B	Forward P/E	-	EPS next Y	-1.14	Insider Trans	0.00%	Shs Float	65.28M	Perf Month	-13.13%
Income	-152.81M	PEG	-	EPS next Q	-0.08	Inst Own	30.44%	Short Float	2.18%	Perf Quarter	-23.98%
Sales	582.71M	P/S	3.34	EPS this Y	-123.18%	Inst Trans	-0.89%	Short Ratio	11.32	Perf Half Y	-15.01%
Book/sh	42.12	P/B	0.70	EPS next Y	-41.98%	ROA	-3.19%	Short Interest	1.42M	Perf Year	-23.09%
Cash/sh	61.24	P/C	0.48	EPS next 5Y	47.44%	ROE	-5.65%	52W Range	29.79 - 45.21	Perf YTD	-27.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5.49%	52W High	-34.73%	Beta	0.26
Dividend TTM	-	Quick Ratio	8.78	Sales past 5Y	16.83%	Gross Margin	96.76%	52W Low	-0.94%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	8.91	EPS Y/Y TTM	-3035.40%	Oper. Margin	-37.29%	RSI (14)	15.89	Volatility	1.76% 1.51%
Employees	1123	Debt/Eq	0.01	Sales Y/Y TTM	-7.12%	Profit Margin	-26.22%	Recom	2.50	Target Price	46.49
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	29.37%	Payout	0.00%	Rel Volume	1.82	Prev Close	29.80
Sales Surprise	367.82%	EPS Surprise	220.78%	Sales Q/Q	-4.78%	Earnings	Feb 22 AMC	Avg Volume	125.45K	Price	29.51
SMA20	-8.16%	SMA50	-15.64%	SMA200	-20.94%	Trades		Volume	150,794	Change	-0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Downgrade	BofA Securities	Neutral → Underperform	$41 → $31
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight	$38
Aug-24-23	Downgrade	Citigroup	Buy → Neutral
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-23	Upgrade	Jefferies	Underperform → Hold	$49 → $47.20
Nov-07-22	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$80 → $61
Jan-27-22	Upgrade	Citigroup	Neutral → Buy
Aug-19-21	Downgrade	Barclays	Overweight → Equal Weight
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Apr-20-21	Initiated	Deutsche Bank	Buy
Apr-14-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-23-21	Upgrade	BofA Securities	Underperform → Neutral	$93 → $94
Feb-19-21	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-19-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$159 → $129
Nov-19-20	Initiated	Maxim Group	Buy	$170
Oct-21-20	Downgrade	Goldman	Neutral → Sell
Aug-25-20	Downgrade	Jefferies	Buy → Hold
Aug-24-20	Downgrade	H.C. Wainwright	Buy → Neutral	$270 → $123

Show Previous Ratings

Apr-04-24 04:01PM	Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 (GlobeNewswire)
Apr-03-24 09:35AM	After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) (Zacks)
Mar-28-24 04:01PM	Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings (GlobeNewswire)
Mar-26-24 04:01PM	Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board (GlobeNewswire)
Mar-18-24 09:35AM	Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround (Zacks)
05:20PM	Loading…
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-24-24 08:30AM	Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 04:01PM	Galapagos announces full year 2023 results and outlook for 2024 (GlobeNewswire)
04:01PM	Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline (GlobeNewswire)
Feb-15-24 04:01PM	Galapagos presents at EBMT-EHA annual meeting 2024 (GlobeNewswire)
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-31-24 04:01PM	Galapagos completes transaction to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Jan-04-24 04:01PM	Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
Jan-03-24 04:01PM	Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology (GlobeNewswire)
04:01PM	BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets (PR Newswire)
01:00AM	Loading…
Jan-02-24 01:00AM	Galapagos signs agreement to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Dec-19-23 04:01PM	Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 (GlobeNewswire)
Dec-09-23 12:00PM	Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 (GlobeNewswire)
Dec-07-23 04:01PM	Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 (GlobeNewswire)
Nov-06-23 10:32AM	Galapagos NV (NASDAQ:GLPG) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:45AM	Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care (PR Newswire)
Nov-02-23 04:01PM	Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 (GlobeNewswire)
Oct-30-23 04:01PM	Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma (GlobeNewswire)
Sep-19-23 04:01PM	Galapagos appoints Simon Sturge to its Board of Directors (GlobeNewswire)
Aug-28-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus (GlobeNewswire)
Aug-03-23 04:01PM	Galapagos announces first half-year 2023 financial results (GlobeNewswire)
Jun-15-23 04:01PM	Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer (GlobeNewswire)
Jun-12-23 04:01PM	Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board (GlobeNewswire)
Jun-05-23 04:01PM	Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress (GlobeNewswire)
May-23-23 04:01PM	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis (GlobeNewswire)
04:01PM	Loading…
May-22-23 04:01PM	Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 (GlobeNewswire)
May-05-23 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire) +5.90%
May-04-23 04:01PM	Galapagos announces first quarter 2023 financial results (GlobeNewswire)
May-02-23 04:01PM	Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
Apr-26-23 04:01PM	Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis (GlobeNewswire)
Apr-25-23 04:01PM	Galapagos shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders meeting (GlobeNewswire)
Mar-30-23 04:30PM	Galapagos and NovAliX enter into an integrated drug discovery collaboration (GlobeNewswire)
Mar-23-23 04:01PM	Galapagos publishes 2022 annual report and announces Annual Shareholders Meeting (GlobeNewswire)
Mar-20-23 04:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Feb-27-23 04:01PM	Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 (GlobeNewswire)
Feb-23-23 04:01PM	Galapagos announces full year 2022 results and outlook for 2023 (GlobeNewswire)
Feb-09-23 04:01PM	Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL (GlobeNewswire) -7.34%
Feb-08-23 04:01PM	Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohns disease (GlobeNewswire)
Jan-10-23 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Jan-03-23 04:01PM	Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Dec-22-22 04:01PM	Galapagos announces changes to Executive Committee (GlobeNewswire)
Dec-16-22 09:55AM	Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect? (Zacks)
Dec-13-22 01:00AM	Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care (GlobeNewswire)
Dec-08-22 09:35AM	Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround (Zacks)
Nov-11-22 07:15AM	Galapagos announces CHMP adoption of PRACs recommendation for Jyseleca® following extensive safety review of all JAK inhibitors (GlobeNewswire)
Nov-08-22 04:01PM	Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 (GlobeNewswire)
Nov-04-22 04:01PM	Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022 (GlobeNewswire) -5.52%
Nov-03-22 04:01PM	Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results (GlobeNewswire)
Nov-02-22 07:15AM	Strong week for Galapagos (AMS:GLPG) shareholders doesn't alleviate pain of three-year loss (Simply Wall St.)
Oct-17-22 01:30AM	Galapagos to host its R&D Update 2022 in New York on 4 November 2022 (GlobeNewswire)
Oct-06-22 04:01PM	Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress (GlobeNewswire)
Oct-03-22 04:01PM	Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies (GlobeNewswire)
Sep-29-22 03:59PM	3 Biotech Stocks to Sell in October (InvestorPlace)
Sep-27-22 04:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Sep-13-22 10:21AM	Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength? (Zacks) -5.39%
Aug-29-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-24-22 04:01PM	Galapagos to present at upcoming investor conferences (GlobeNewswire)
Aug-18-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-08-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
Aug-04-22 04:01PM	First key steps in pipeline rebuild and strong commercial progress in H1 2022 (GlobeNewswire)
Jun-29-22 09:40AM	Are Medical Stocks Lagging Galapagos (GLPG) This Year? (Zacks)
Jun-22-22 06:39AM	Galapagos Bets 225M On CellPoint Marking Its Entry Into CAR-T Field (Benzinga)
Jun-21-22 04:03PM	Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies (GlobeNewswire)
Jun-20-22 04:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Jun-09-22 09:55AM	Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High? (Zacks)
Jun-02-22 09:40AM	Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-01-22 04:01PM	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
May-25-22 04:01PM	Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress (GlobeNewswire)
May-24-22 09:35AM	Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine (Benzinga)
May-16-22 09:40AM	Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year? (Zacks)
May-11-22 09:47AM	Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs (Zacks)
May-09-22 03:30PM	RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value (Benzinga) -5.20%
May-06-22 04:01PM	Galapagos creates new subscription right plans (GlobeNewswire)
May-05-22 04:01PM	Galapagos demonstrates regulatory and commercial progress in Q1 2022 (GlobeNewswire)
Apr-28-22 09:40AM	Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-26-22 04:01PM	Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board (GlobeNewswire)
Apr-04-22 09:10AM	Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength? (Zacks)
Mar-28-22 02:01AM	Jyseleca® approved in Japan for ulcerative colitis (GlobeNewswire)
Mar-24-22 04:17PM	Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings (GlobeNewswire)
04:17PM	Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings (GlobeNewswire)
Mar-18-22 05:01PM	Galapagos increases share capital through subscription right exercises (GlobeNewswire)
Feb-24-22 04:01PM	Galapagos 2021 results set stage for future growth (GlobeNewswire)
Feb-03-22 04:01PM	Galapagos receives transparency notification from EcoR1 Capital (GlobeNewswire)
Feb-02-22 04:01PM	Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohns and Colitis Organization (ECCO) annual congress (GlobeNewswire)
Jan-27-22 06:07PM	Why Galapagos Trounced the Market Today (Motley Fool) +22.47%
10:15AM	Former J&J Scientist Stoffels to Lead Galapagos Revival Bid (Bloomberg)
07:50AM	Galapagos Surges On New CEO and Upgrade News (Investing.com)
Jan-26-22 06:01PM	Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO (Reuters)
04:40PM	Galapagos creates new subscription right plan (GlobeNewswire)
04:01PM	Galapagos appoints Paul Stoffels as Chief Executive Officer (GlobeNewswire)
Jan-18-22 04:01PM	JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN (GlobeNewswire)
Jan-14-22 11:42AM	Is Galapagos NV (GLPG) A Good Stock To Buy? (Insider Monkey) +5.91%
Jan-13-22 04:01PM	Galapagos creates new subscription right plan (GlobeNewswire)
Jan-06-22 09:30AM	Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLPG

Galapagos NV ADR

Upgrade your FINVIZ experience